Colen Sascha, Geervliet Pieter, Haverkamp Daniël, Van Den Bekerom Michel P J
Department of Orthopaedic Surgery, University Hospitals Leuven, Pellenberg, Belgium ; Department of Orthopaedic Surgery and Traumatology, Hümmling Hospital Sögel, Sögel, Germany.
Department of Orthopaedic Surgery, Gemini Hospital, Den Helder, Amsterdam, the Netherlands.
Int J Shoulder Surg. 2014 Oct;8(4):114-21. doi: 10.4103/0973-6042.145252.
Conservative treatments are especially in patients with glenohumeral osteoarthritis (GH-OA) important, since shoulder arthroplasty has its limitations. In this systematic review, we will evaluate the current evidence regarding the efficacy of intra-articular (IA) infiltration treatment options in patients with GH-OA.
The following databases are searched: Pubmed/Medline, Cochrane Clinical Trial Register, Embase and the WHO clinical trial register. All IA injection products used for the treatment of shoulder OA in humans are included.
A total of 8 studies could be included in this review. Hyaluronic acid (HA) showed effect sizes of 2.07, 2.02 and 2.11 at 6, 12 and 26 weeks follow-up, respectively. Placebo (1.60, 1.82 and 1.68) also showed stable effect sizes at the same time points. The efficacy of corticosteroids (CS) decreased rapidly at follow-up (1.08, 0.43 and 0.19). Although statistical significant, the maximum difference in effect sizes between HA and placebo was only 0.43 with absolute values between 2.0 and 6.4 on a 100-point visual analogue score for pain.
IA treatment with HA has a good efficacy at follow-up compared to baseline. However, the difference in efficacy between HA and placebo never reaches the minimal clinically important difference at any of the follow-up points. We are not able to give clear recommendations for the use of IA CS injections in patients with GH-OA. In future research, we recommend focusing on sufficiently powered randomized trials to compare the efficacies of HA, CS, placebo and other IA treatment options in patients with GH-OA.
保守治疗对于肩肱关节骨关节炎(GH - OA)患者尤为重要,因为肩关节置换术存在局限性。在本系统评价中,我们将评估目前关于关节内(IA)浸润治疗方案对GH - OA患者疗效的证据。
检索了以下数据库:PubMed/Medline、Cochrane临床试验注册库、Embase和世界卫生组织临床试验注册库。纳入所有用于治疗人类肩部骨关节炎的IA注射产品。
本评价共纳入8项研究。透明质酸(HA)在随访6周、12周和26周时的效应量分别为2.07、2.02和2.11。安慰剂(1.60、1.82和1.68)在相同时间点也显示出稳定的效应量。皮质类固醇(CS)的疗效在随访时迅速下降(1.08、0.43和0.19)。尽管具有统计学意义,但在100分的疼痛视觉模拟评分上,HA与安慰剂之间效应量的最大差异仅为0.43,绝对值在2.0至6.4之间。
与基线相比,HA的IA治疗在随访时具有良好疗效。然而,HA与安慰剂之间的疗效差异在任何随访点均未达到最小临床重要差异。我们无法对GH - OA患者使用IA CS注射给出明确建议。在未来的研究中,我们建议专注于开展足够样本量的随机试验,以比较HA、CS、安慰剂和其他IA治疗方案对GH - OA患者的疗效。